RENAL CELL CARCINOMA (KIDNEY CANCER)

This study compares two surgical approaches for high-risk kidney cancer: a standard limited lymph node removal versus a more thorough 'template' dissection. Researchers want to see if the more extensive surgery helps prevent cancer from returning and improves survival. About 220 …

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This study tests whether a digital app that tracks symptoms weekly can help doctors better manage side effects in people with advanced kidney cancer taking cabozantinib and nivolumab. About 83 patients will use the app to report how they feel, and doctors can adjust treatment bas…

This phase 3 trial tests a drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for adults with advanced clear cell kidney cancer that has returned or spread after prior treatments. The study first finds the best dose, then compares it to stan…

This Phase III trial is testing whether adding a precise type of radiation (SBRT) to standard drug therapy (targeted drugs and/or immunotherapy) can help people with kidney cancer that has spread to up to five spots live longer without the disease getting worse. The study will en…

This pilot study is testing whether it's practical to add an abdominal CT scan to the standard lung cancer screening for people aged 55-70 who have smoked. The goal is to see if this extra scan can detect kidney cancer, abdominal aortic aneurysms, and kidney stones without slowin…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors ca…

This study uses data from 4,700 kidney cancer patients treated at a single hospital over 12 years. The goal is to create a new model that better predicts how the disease will progress, especially for patients with a tumor thrombus. Researchers will also test whether using this mo…

This study looks at fear of cancer recurrence in people who had surgery for kidney cancer and their partners. Researchers are working with patients to create better ways to ask about and measure this fear. The goal is to improve follow-up care by understanding what matters most t…

This study is observing 300 adults with kidney, bladder, lung, or liver cancer who are starting immunotherapy (PD-1/PDL-1 inhibitors). Researchers will measure a protein called Galectin-3 in the blood before each treatment to see if its level is linked to how well the therapy wor…